LBLyudmila Belenska-Todorova

Lyudmila Belenska-Todorova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lyudmila Belenska-Todorova has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic Profile And Educational Needs Of Children With Autism Spectrum Disorders: Perspectives On Long-Term Support And Inclu-sion (ICF-CY)

    by Milen Zamfirov Zamfirov, Margarita Angelova Stefanova Bakracheva, Kaloyan Ivanov Damyanov, Lyudmila Filipova Belenska-Todorova, Polina Ivanova Daskalova-Petkova

    Over the years, research has demonstrated that individuals with autistic spectrum disor-ders are a heterogeneous group. In recent years, the concept of inclusive education has provided additional insight into the possibilities of working with children with ASD in mainstream schools. The purpose of this study is to outline the specific strengths, capaci-ties, and opportunities for supporting children and students with ASD in mainstream schools. The Classification of Functioning, Disability, and Health for Children and Youth (ICF-CY) indicators were used as a basis and applied to different forms of ASD diagnosis, looking for more detailed individual profiles and differences by gender, age, and between different diagnoses, and according to specific difficulties and areas where children and students do not have difficulties. The study comprises 164 children and students, aged 3-19 years. The results highlight the strengths and resources of a large number of the re-spondents with ASD, outlining their resources in communication, language mastery and thinking. From one-fifth to more than half of the respondents do not encounter challenges when the environment and context are supportive.

  • Open Access

    Exome Study of Single Nucleotide Variations in Patients with Syndromic and Non-Syndromic Autism Strongly Supports the Hypothesis for Its Genetic Basis

    by Lyudmila Belenska-Todorova, Milen Zamfirov, Tihomir Todorov, Slavena Atemin, Mila Sleptsova, Zornitsa Pavlova, Ales Maver, Borut Peterlin, Albena Todorova

    Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interaction, communication deficits, and the presence of repetitive, restricted behavioral patterns and interests. Recent research shows that it occurs due to the mutations related to the development of the nervous system, combined with the impact of various environmental factors. This necessitates the identification of the genetic variations involved in ASD pathogenesis. We performed whole exome sequencing (WES) in a cohort of 22 Bulgarian male and female individuals showing ASD features alongside with segregation analyses of their families. A targeted panel of genes was chosen and analyzed for each case, based on a detailed examination of clinical data. Gene analyses revealed that specific variants concern key neurobiological processes involving neuronal architecture, development and function such as synaptic signaling imbalance, ciliopathies, spectrins structure, neuronal organelles trafficking and integrity, gene expression, cell cycle control, mitochondrial function, and neuron homeostasis. Our data contribute to a better understanding of the complex neurobiological features of autism and are applicable in the diagnosis and development of personalized therapeutic approaches.


  • Open Access

    Changes in the Subchondral Bone, Visfatin, and Cartilage Biomarkers after Pharmacological Treatment of Experimental Osteoarthritis with Metformin and Alendronate

    by Sevdalina Nikolova Lambova, Nina Ivanovska, Stela Stoyanova, Lyudmila Belenska-Todorova, Elenka Georgieva, Tsvetelina Batsalova, Dzhemal Moten, Desislava Apostolova, Balik Dzhambazov

    Subchondral bone that has intense communication with the articular cartilage might be a potential target for pharmacological treatment in the early stages of osteoarthritis (OA). Considering the emerging data about the role of adipokines in the pathogenesis of OA, the administration of drugs that influence their level is also intriguing. Metformin and alendronate were administered in mice with collagenase-induced OA (CIOA) as a monotherapy and in combination. Safranin O staining was used for the assessment of changes in subchondral bone and articular cartilage. Before and after treatment, serum levels of visfatin and biomarkers of cartilage turnover (CTX-II, MMP-13, and COMP) were assessed. In the current study, the combined administration of alendronate and metformin in mice with CIOA led to the protection against cartilage and subchondral bone damage. In mice with CIOA, metformin led to a decrease in visfatin level. In addition, treatment with metformin, alendronate, or their combination lowered the level of cartilage biomarkers (CTX-II and COMP), while the level of MMP-13 was not influenced. In conclusion, personalized combination treatment in OA according to clinical phenotype, especially in the early stages of the disease, might lead to the identification of a successful disease-modifying therapeutic protocol in OA.


  • Open Access

    Serum Leptin and Resistin Levels in Knee Osteoarthritis—Clinical and Radiologic Links: Towards Precise Definition of Metabolic Type Knee Osteoarthritis

    by Sevdalina Nikolova Lambova, Tsvetelina Batsalova, Dzhemal Moten, Stela Stoyanova, Elenka Georgieva, Lyudmila Belenska-Todorova, Desislava Kolchakova, Balik Dzhambazov

    Obesity is considered a major risk factor for the development and progression of knee osteoarthritis (OA). Apart from the mechanical effect of obesity via increase in mechanical overload of weight-bearing joints, an association with hand OA has been observed. There has been increasing interest in the role of adipokines in the pathogenesis of OA in the recent years. It has been suggested that their systemic effects link obesity and OA. In this regard, the aim of the current study was measurement and analysis of serum levels of leptin and resistin in patients with knee OA with different body mass index (BMI). Seventy-three patients with primary symptomatic knee OA at the age between 35 and 87 years (mean age 66 years) were included in the study (67 women and 6 men). The patients were from 2nd to 4th radiographic stage according to Kellgren–Lawrence scale. 43 patients were with concomitant obesity (BMI ≥ 30 kg/m2, mean values 38.34 ± 8.20) and 30 patients with BMI < 30 kg/m2 (mean values 25.07 ± 2.95). Eleven individuals with different BMIs, including cases with obesity but without radiographic knee OA, were examined as a control group. Serum levels of leptin and resistin were measured via ELISA method. In patients with knee OA and BMI ≥ 30 kg/m2, serum levels of leptin (39.546 ± 12.918 ng/mL) were significantly higher as compared with healthy individuals (15.832 ± 16.531 ng/mL, p < 0.05) and the patients with low BMI (p < 0.05). In patients with BMI < 30 kg/m2 the levels of leptin (13.010 ± 10.94 ng/mL) did not differ significantly from the respective values in the control group (p = 0.48). Serum levels of resistin were also higher in knee OA patients in comparison with healthy controls, but the difference was statistically significant only for patients with high BMI (2.452 ± 1.002 ng/mL in the group with BMI ≥ 30 kg/m2; 2.401 ± 1.441 ng/mL in patients with BMI < 30 kg/m2; 1.610 ± 1.001 ng/mL in the control group, p < 0.05). A correlation was found between the serum levels of leptin and radiographic stage of OA, i.e., higher leptin levels were present in the more advanced 3rd and 4th radiographic stage, while for resistin a correlation was observed in the patient subgroup with BMI < 30 kg/m2. Serum leptin and resistin levels and clinical characteristics were analyzed in patients with different clinical forms of OA. Novel clinical correlations have been found in the current study in patients with isolated knee OA vs. cases with presence of other disease localizations. It has been observed that patients with isolated knee OA were significantly younger and had higher BMI as compared with cases in whom OA is combined with other localizations i.e., spondyloarthritis ± presence of hip OA and with generalized OA. This supports the hypothesis that presence of obesity promotes earlier development of knee OA as an isolated localization of the disease in younger patients before appearance of osteoarthritic changes at other sites. The levels of leptin and resistin in isolated knee OA were also higher. Serum levels of leptin and resistin in combination with patients’ clinical characteristics suggest existence of different clinical and laboratory profile through which more precise definition of metabolic phenotype of knee OA would be possible. Considering the fact that obesity is a modifiable risk factor that has an impact on progression of knee OA, different approaches to influence obesity may offer potential for future disease-modifying therapeutic interventions.


  • Open Access

    Disease-Modifying Potential of Metformin and Alendronate in an Experimental Mouse Model of Osteoarthritis

    by Lyudmila Belenska-Todorova, Sevdalina Nikolova Lambova, Stela Stoyanova, Elenka Georgieva, Tsvetelina Batsalova, Dzhemal Moten, Desislava Kolchakova, Balik Dzhambazov

    Osteoarthritis (OA) is the most common degenerative joint disease causing progressive damages of the cartilage and subchondral bone, synovial inflammation, and severe pain. Despite the complex pathomorphological changes that occur in OA, the approach to different forms of OA is standardized. The global results from pharmacological treatment are not satisfactory. Hence, this study aimed to explore the effects of metformin, alendronate, and their combination on OA development and progression in mice with collagenase-induced osteoarthritis (CIOA). Female ICR (CD-2) mice were randomized to five groups: control group, CIOA untreated, CIOA + metformin, CIOA + alendronate, and CIOA + metformin + alendronate. OA was induced by the intra-articular (i.a.) injection of collagenase. OA phenotype was analyzed by flow cytometry (bone marrow cell differentiation), ELISA (serum levels of the adipokines leptin and resistin), and histology (pathological changes of the knee joint). Treatment with metformin, alendronate, or their combination inhibited the expression of RANK and RANKL on osteoblasts and osteoclasts obtained by ex vivo cultivation of bone marrow cells in mineralization or osteoclastogenic media. In addition, metformin treatment was effective for the attenuation of fibroblast differentiation, but not of mesenchymal stem cells (MSCs), while alendronate had an opposite effect. The combination of metformin and alendronate had a suppressive effect on both MSCs and fibroblasts differentiation. Treatment with metformin, alendronate, and their combination decreased serum concentrations of leptin and resistin in the chronic phase of arthritis. The histopathological examination showed that compared with the untreated CIOA group (OA score 9), the groups treated with metformin (OA score 4) or alendronate (OA score 6) had lower scores for cartilage changes. Metformin combined with alendronate significantly decreased the degree of cartilage degeneration (OA score 2), suggesting that this combination might be a useful approach for the treatment of OA patients.